Bovine Pericardial Valve Market Report 2026

The bovine pericardial valve market size has grown strongly in recent years. It will grow from $1.57 billion in 2025 to $1.72 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to rising prevalence of valvular heart diseases in aging population, increasing adoption of open heart surgical valve replacement procedures, advancements in cardiac surgery techniques and perioperative care, growing availability of bioprosthetic valve options in hospitals, increasing awareness of cardiovascular disease treatment options.

The bovine pericardial valve market size is expected to see rapid growth in the next few years. It will grow to $2.53 billion by 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for minimally invasive and transcatheter procedures, rising global geriatric population driving valve replacement needs, advancement in tissue engineering and biomaterial innovation, growing preference for durable and low anticoagulation valve solutions, expanding healthcare infrastructure and cardiac care accessibility in emerging markets. Major trends in the forecast period include increasing adoption of advanced bioprosthetic heart valve materials with enhanced durability, rising demand for minimally invasive valve replacement procedures, growing focus on anti calcification treatment technologies in tissue valves, expansion of transcatheter heart valve implantation procedures, increasing clinical preference for long lasting biologic valve substitutes over mechanical valves.

The rising prevalence of cardiovascular diseases is expected to propel the growth of the bovine pericardial valve market going forward. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including coronary artery disease, ischemic heart disease, heart failure, and valvular conditions, and remain the leading cause of global morbidity and mortality. The increasing prevalence of cardiovascular diseases is primarily contributing to market expansion due to rising sedentary lifestyles. Reduced physical activity slows metabolic processes and encourages obesity, which significantly elevates the risk of heart-related disorders. The bovine pericardial valve supports cardiovascular diseases by providing a durable and highly biocompatible option for surgical valve replacement in patients suffering from CVDs, particularly in valvular heart disease cases that require long-term performance and a reduced likelihood of reoperation. For instance, in September 2025, according to the American College of Cardiology, a US-based medical association, cardiovascular disease deaths worldwide increased to 19.2 million in 2023, up from 2022. Therefore, the rising prevalence of cardiovascular diseases is contributing and propelling the growth of the bovine pericardial valve market.

The increasing preference for minimally invasive procedures is expected to propel the growth of the bovine pericardial valve market going forward. Minimally invasive procedures are medical interventions designed to minimize bodily trauma by utilizing small incisions or natural body openings, resulting in reduced pain, lower complication risks, and faster recovery compared to conventional open surgeries. The growing preference for minimally invasive procedures is largely supported by technological advancements in surgical instruments and techniques, which have enabled clinicians to perform complex cardiac interventions with greater precision and significantly improved patient recovery outcomes. The rising adoption of minimally invasive approaches is further contributing to increased utilization of bovine pericardial valves, as these tissue-based valves are well-suited for delivery through catheter-based and other minimally invasive cardiac surgical platforms. For instance, in June 2024, according to the American Society of Plastic Surgeons (ASPS), a US-based professional medical organization, more than 11,000 board-certified plastic surgeons worldwide reported that minimally invasive procedures grew by 7% in 2023 compared to 2022, with nearly 25.4 million such procedures performed in the United States in 2023, up from approximately 23.7 million in 2022. Therefore, the increasing preference for minimally invasive procedures is contributing and propelling the growth of the bovine pericardial valve market.

Leading companies operating in the bovine pericardial valve market are focusing on developing advanced products, such as next-generation surgical aortic tissue valves, to enhance procedural efficiency and long-term patient outcomes. A next-generation surgical aortic tissue valve is an advanced bioprosthetic valve designed to replace a diseased aortic valve with improved durability and performance. It enhances blood flow efficiency and reduces complications, supporting better patient outcomes. For example, in April 2024, Medtronic, an Ireland-based medical technology company, launched the Avalus Ultra Valve, a next-generation surgical aortic tissue valve designed to enhance ease of use during implantation and support lifetime patient management. The Avalus Ultra Valve features advanced tissue treatment for improved durability, optimized leaflet design for enhanced hemodynamic performance, and user-friendly handling characteristics that simplify surgical procedures, contributing to consistent clinical outcomes and long-term valve reliability.

Major companies operating in the bovine pericardial valve market are Shanghai Cingular Biotechnology Co Ltd, Medtronic plc, Edwards Lifesciences Corporation, Meril Life Sciences Pvt Ltd, Lepu Medical Technology Beijing Co Ltd, MicroPort Scientific Corporation, Braile Biomédica Indústria Comércio e Representações SA, Venus Medtech Hangzhou Inc, Peijia Medical Limited, Artivion Inc, Balance Medical Limited, HighLife SAS, Maverick Biosciences Inc.

North America was the largest region in the bovine pericardial valve market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bovine pericardial valve market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bovine pericardial valve market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bovine pericardial valve market consists of sales of bioprosthetic heart valve leaflets, pericardial tissue patches, cardiac repair membranes, and valve reconstruction grafts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.